Abstract: is produced by the small intestine, is associated with chylomicrons, and appears to be a suitable marker for clinical studies of postprandial dynamics of lipoproteins. It is also associated with cardiovascular risk factors. We have developed an assay system to quantify immuno-reactive apoB-48 in rabbit serum or plasma. A microtiter-plate was coated with monoclonal antibody raised against human apoB-48 C-terminal specific decapeptide that has high homology to the rabbit C-terminal sequence. Appropriate ELISA standard curves were obtained using apoB-48 extracted from rabbit serum by immuno-affinity chromatography. No cross-reactivity was found with apoB-100 in western blot analyses. Intra-and inter-assay CVs were less than 3%. Recovery of rabbit apoB-48 spiked in serum was within 93.4-105%. ApoB-48 levels in healthy controls rabbits fed a normal diet were within the range of 0.903-1.09 µg/ml (mean ± SD: 1.03 ± 0.084 µg/ml). In healthy animals, the blood apoB-48 level was markedly increased by a high fat diet and in the postprandial state in parallel with serum triglyceride. Ezetimibe, cholesterol absorption inhibitor, given orally to rabbits fed on a high fat diet blocked further increase of blood levels of apoB-48 and triglyceride. This method for measuring apoB-48 using the monoclonal antibody is simple, reliable, and suitable for routine analyses.
Introduction
Apolipoprotein B-48 (apoB-48) is the most appropriate marker for the estimation of postprandial lipoproteins because it is associated exclusively with intestinally derived chylomicrons (CMs) and their remnants which are circulating particles that have been described as atherogenic [6] . Because of the high homology of hepatic apoB-100 with apoB-48, quantification of apoB-48 by immunoassay using a specific antibody has been difficult. Furthermore, in the fasting state, the plasma apoB-48 concentration is about 100-fold lower than the concentration of apoB-100.
For animal experiments on lipoprotein transport and metabolism, rats or mice are unsuitable because they lack the cholesterol ester transport protein (CETP). However rabbits are suitable due to the presence of CETP and their cholesterol transport system is thought -Original-to be similar to that of humans. Most attempts to quantify apoB-48 have used analytical electrophoresis (SDS-PAGE) with densitometric scanning of Coommassie Brilliant Blue-stained gels [3, 7, 9, 15] . In 1993, Peel et al. [12] reported a specific antiserum raised against apoB-48 that was later used by Lovegrove et al. [10] in 1996 to develop an ELISA to quantify apoB-48 in human triglyceride-rich lipoproteins (TRLs). The apoB-48 Cterminal heptapeptide (consisting of an N-terminal cysteine residue attached to the C-terminal hexapeptide equivalent to residues 2147-2152 of apoB-48) was used as the immunogen to raise the polyclonal antibody used in this assay. Uchida et al. [16] later developed an apoB-48 ELISA method using the same C-terminal peptide as the immunogen for monoclonal antibody production. No cross-reactivity was found with apoB-100, as verified by ELISA and western blot analyses using polyclonal and monoclonal antibodies.
In a previous study, we established an ELISA system for human apoB-48 using monoclonal antibody raised against apoB-48 C-terminal decapeptide [8] . This method proved to be simple and reliable for measuring apoB-48 in human serum or plasma, and is suitable for routine analyses. Here, we describe the development and evaluation of an ELISA system for rabbit apoB-48 that will be useful in animal experiments.
Materials and Methods

Materials
Japanese White rabbit serum and male New Zealand White (NZW) rabbits were purchased from Kitayama LABES Co., Ltd., (Nagano, Japan). All animal care and experimentation were conducted in accordance with the guidelines of Shibayagi Co., Ltd. Ezetimibe (Zetia, Schering-Plough) was purchased from Koshin Chemicals, Takasaki, Gunma, Japan.
Collection of blood samples from normal rabbits fed on a high fat diet
Four healthy male NZW rabbits of 10 weeks of age, body weight 2-2.5 kg, which had been fed on a standard diet for rabbits (LRC-4, Oriental Yeast Co., Ltd., Tokyo, Japan) were given a high fat diet, LRC-4, containing 1% cholesterol and 6% peanuts oil, about 450 kcal/100 g for 7 days (Day 1 until Day 7), then fasted for 18 h, given the high fat diet again for 1 h, after which the diet was withdrawn. Blood samples were obtained from the ear vein on Day 1, before the start of high fat diet, on Day 8 at the end of the fasting period, and 1, 3, 6, 9 h after the re-start of feeding. Sera were separated, and stored at -80°C until measurement of apoB-48 and triglyceride.
Ezetimibe administration to rabbits fed on a high fat diet
Six male NZW rabbits of 10 weeks of age, 2.5 kg body weight, were divided into 2 groups, and both groups were given the high fat diet, LRC-4, containing 1% cholesterol and 6% peanuts oil, about 450 kcal/100 g, for 7 days starting on Day 1. Rabbits in group 1 were orally administered ezetimibe, a cholesterol absorption inhibitor, 0.6 mg/kg body weight/day suspended in 3 ml of physiological saline for 2 weeks starting on Day 8, while rabbits in group 2 served as a control and were given 3 ml of physiological saline for 2 weeks starting on Day 8. Blood samples were collected on Days 1, 8, 15, and 22 from the ear vein. After sampling, sera were separated, and kept at -35°C until assays for apoB-48, triglyceride, and total cholesterol.
Blood triglyceride and cholesterol measurement
Blood triglyceride concentration was determined using a triglyceride kit, L-type (Wako Pure Chemical Industries, Ltd., Tokyo, Japan), and a Hitachi Automatic Analyzer 7070, while cholesterol concentration was measured with Cholesterol E-HA test (Wako Pure Chemical Industries).
C-terminal peptide and its monoclonal antibody
As the amino acid sequence of rabbit apoB- 48 has not yet been fully clarified we compared the partially known sequence of rabbit B-48 to that of the fully known human B-48 sequence. We found that the C-terminal decapeptide of the rabbit apoB-48 sequence, KLSQLQTYVI [14] , has very high homology to that of human apoB-48, KLSQLQTYMI. In a previous study, we produced a monoclonal antibody to human decapeptide (4C8), and successfully applied it to human apoB-48 assay [8] . In this study we tested the possibility of using this mono-clonal antibody to capture rabbit apoB-48. The details of monoclonal antibody preparation were described in our previous report [8] .
Briefl y, a peptide, C-KLSQLQTYMI (with N-terminal cysteine for coupling to the carrier molecule) was synthesized on a peptide synthesizer and conjugated with Keyhole Limpet Hemocyanine (KLH) (EDM Bioscience Inc., San Diego, CA, USA) by the action of N-(gammamaleimido-butyrylloxy) succinimide ester (Pierce, Rockford, IL, USA) in NN-dimethyl formamide (Sigma, St. Louis, MO, USA)/0.1 M phosphate buffer (PB) pH 7.5. C-10-KLH was emulsifi ed with Freund's complete adjuvant and immunized into a BALB/c mouse. After a boosting with immunogen, fusion of spleen cells with myeloma cells (P3U1) was carried out with PEG (1,500, Boehringer, Ingelheim, Germany) followed by screening for the desired hybridoma reactive only to apoB-48. The western blot method was utilized for screening.
Binding of this monoclonal antibody, 4C8, to rabbit apoB-48 was confi rmed by the dot blot method in which synthesized C-terminal decapeptide of rabbit apoB-48 (KLSQLQTYVI) was spotted and stained with 4C8 [14] ( Fig. 1) .
Two microliters of 0.2 µM C-terminal decapeptide of rabbit apoB-48 (KLSQLQTYVI) or recombinant human apoB-48 [17] were spotted onto a nitrocellulose membrane (Bio-Rad, Tokyo, Japan), and fi xed and washed with physiological saline solution. Then, the membrane was rinsed with 25% Block-ace for 120 min at 25°C, washed again with saline, and incubated with anti apoB-48 monoclonal antibody (4C8) diluted to 1:500 for 15 h at 4°C. After washing with saline, the membrane was further incubated with anti-mouse IgG-HRP, and washed. Blots were visualized by the addition of peroxidase substrate, 4-chloro-1-naphthol, in diethylenglycol.
SDS-PAGE and immunoblotting
SDS-PAGE was performed to separate serum proteins, and followed by western blotting, to determine the presence of apoB-48. We used SDS-PAGE mini 4-20% gradient gels (1.0 mm, TEFCO, Hachioji, Japan), polyacrylamide gradient gels designed for separation of highmolecular mass proteins. Rabbit serum samples were mixed with an equal volume of sample buffer containing 0.5 M Tris-HCl, pH 6.8, 10% glycerol 10% SDS, and 0.1% BPB. After 100 min, they were loaded onto SDS-PAGE gels and electrophoresed at 100 V, 18 mA, for 90 min at 15°C, followed by staining with CBB Stain kit (Kanto Chemical., Inc., Tokyo, Japan).
After electrophoresis, the proteins were electro-transferred directly onto a nitrocellulose membrane (100 V, 170 mA, 60 min) using the Phast system. After washing with physiological saline solution, the nitrocellulose membrane was rinsed with 25% Block-ace for 120 min at 25°C, then washed again with saline, and incubated with anti apoB-48 monoclonal antibody (4C8) diluted to 1:500 for 15 h at 4°C. After washing with saline, the membrane was further incubated with anti mouse IgG-HRP, and washed. Apolipoprotein blots were visualized by the addition of peroxidase substrate, 4-chloro-1-naphthol, in diethyleneglycol (Fig. 2) .
Preparation of rabbit apoB-48 standard by immunoaffi nity chromatography using monoclonal antibody
To 3 ml of normal Japanese White rabbit serum, TritonX-100 was added to a fi nal concentration of 0.5%. It was mixed for 30 min, and then dialyzed against 5,000 ml of 10 mM PB, pH 7.2 with 0.15 M NaCl (PBS). The dialysate was applied to an affi nity column packed with anti-apoB-48 (4C8) IgG-bound Sepharose with a binding buffer 10 mM PBS, pH 7.2. It was then eluted with 3 M NaSCN, and 0.3 ml fractions were obtained while checking the UV absorption at 280 nm (Fig. 3) [5, 13] . Fractions Nos. 21-23 were collected together, and dialyzed against 10 mM PBS, pH 7.2 (2,000 ml, twice). The 1: Saline 2: C-terminal decapeptide of rabbit apoB-48 3: Recombinant human apoB-48 Fig. 1 . Dot blot patterns of synthesized C-terminal decapeptide. Binding of the monoclonal antibody, 4C8, to rabbit apoB-48 was confi rmed by the dot blot method in which synthesized C-terminal decapeptide of rabbit apoB-48 (KLSQLQTYVI) was spotted and stained with 4C8.
dialysate was centrifuged at 2,800 rpm for 30 min at 4°C, and the supernatant fl uid (1.6 ml) was stored in Proclin at a fi nal concentration of 0.05%. This solution was shown to contain 32.86 µg/ml of protein by the BCA test. All the processes were performed at 2-8°C (Fig.  3) .
The affi nity-purifi ed product was tested by SDS-PAGE coupled with western blotting as described above. AntiapoB-48/B-100 (ICN Pharmaceuticals Inc., Solon, OH, USA) diluted to 1:1000 was used as the detection antibody (Fig. 4) .
ApoB-48 ELISA protocol
A 96-well microtiterplate (Nalge Nunc International, Tokyo, Japan) was coated by overnight incubation at 4°C with the anti-apoB-48 monoclonal antibody (4C8). After washing the microtiterplate 4 times with 10 mM PBS, Immuno-affi nity chromatographic profi le of apoB-48. To normal Japanese White rabbit serum, TritonX-100 was added to the fi nal concentration of 0.5%, mixed for 30 min, and then dialyzed against 5,000 ml of 10 mM PBS, pH 7.2. The dialysate was applied on an affi nity column packed with anti-apoB-48 (4C8) IgG-bound Sepharose with a binding buffer 10 mM PBS, pH 7.2, then eluted with 3 M NaSCN while checking the UV absorption at 280 nm. Fractions Nos. 21-23 were collected together.
Fig. 4. SDS-PAGE and western blot (WB) pat-
terns of affi nity-purifi ed product. SDS-PAGE and western blotting using antiapoB-48/B-100 (ICN Pharmaceuticals Inc.) diluted to 1:1000 as the detection antibody. Only one positive band was seen between the molecular size markers of 205 and 360 kDa, indicating that the affi nity-purifi ed product was a single substance with a similar molecular size to recombinant human apoB-48 and could react with anti-apoB-48/B-100. pH 7.2, 50-µl aliquots of diluted serum or plasma with a dilution buffer (50 mM Tris-HCl buffer pH 7.5, containing 0.15 M NaCl, and 0.1% TritonX-100) were then added in duplicate to wells. Fifty-microliter aliquots of rabbit apoB-48 standard solution (19.5 to 1,250 ng/ml: 7 points, dissolved in the dilution buffer) were also added in duplicate to the assigned wells for preparing the standard curve. The plate was gently stirred, then incubated at room temperature (20-25°C) for 1 h. After the incubation, the plate was washed 4 times, and 50 µl of biotin-conjugated anti-apoB-48/B-100 (ICN Pharmaceuticals Inc.) diluted with the dilution buffer was added to each well. The plate was stirred, then incubated at room temperature for 1 h. Next, the plate was washed 4 times, 50 µl of HRP-conjugated avidin solution was added, and the plate was incubated at room temperature for 30 min after stirring. After the plate has been washed 4 times, 50 µl of chromogenic substrate solution containing tetramethyl benzidine (TMB+, Dako, Tokyo, Japan), and hydrogen peroxide were added, mixed, and incubated at room temperature for 20 min. The reaction was stopped by adding 50 µl of 1 M H 2 SO 4 . The plate was read at 450 nm, with a sub-wavelength of 620 nm using a Safi re-2 (TECAN, San Jose, CA, USA) plate reader.
Statistical analysis
The results of animal experiments were tested with the F-test for difference of variances, the t-test for difference of means, and one-way analysis of variance (ANOVA) for the time-dependent changes of marker blood levels using Microsoft Excel.
Results
Standard curve for rabbit apoB-48
The product obtained by immuno-affi nity chromatography with anti-apoB48 (4C8) IgG-bound Sepharose was tested by SDS-PAGE and western blotting using antiapoB-48/B-100 (ICN Pharmaceuticals Inc.) diluted to 1:1000 as the detection antibody. Only one positive band was seen between the molecular size markers of 205 and 360 kDa, indicating that the affi nity-purifi ed product was a single substance with a similar molecular size to recombinant human apoB-48 [17] and could react with anti-apoB-48/B-100 (Fig. 4) .
Appropriate standard curves were obtained with apoB-48 isolated by immuno-affi nity chromatography. Figure  5 shows a typical standard curve with concentrations ranging from 19.5 to 1,250 ng/ml. In two-way logarithmic plotting of both apoB-48 concentration and absorbance, the shape of the standard curve was gently curvilinear with standard points locating at nearly equal intervals on both the X and Y axes.
Comparison of the standard curve using the protein preparation extracted by immuno-affi nity chromatography from rabbit serum with that using the recombinant human apoB-48
Two standard curves were prepared using the procedure described above for ELISA. One was obtained using the immuno-affi nity product from rabbit serum as shown in Fig. 3 , and the other was obtained with recombinant human apoB-48 [17] . These standard curves showed an excellent correlation. The equation of fi rst order regression was y = 1.0122x -0.0157, and R 2 was 0.9996 (Fig. 6) .
Assay precision and reproducibility
The assay precision, expressed as intra-assay CVs for 3 samples with different concentrations of apoB-48 in 5 replicate assays were 1.4, 1.2, and 2.3%, respectively. The reproducibility expressed as inter-assay CVs using 2 samples measured in 4 different assays were 0.52 and 1.3%, respectively (n=2).
Validation of the assay system
Specificity: The specificity of the anti-apoB-48 monoclonal antibody (4C8) was verified by ELISA as well as by dot blotting (Fig. 1) and SDS-PAGE with western blotting (Fig. 4) . SDS-PAGE protein staining of serum revealed the presence of apoB-48 and apoB-100, but after immunoblotting, only apoB-48 band was detected between the 205 and 360 kDa markers (Fig. 2) .
In our previous studies, we applied human apoB-100 at concentrations of up to 100-fold greater than the concentration of apoB-48 usually detected, but no crossreactivity (less than 0.01%) was detected [8] .
Spiking Recovery test of apoB-48 in serum: To evaluate the recovery ratio of apoB-48 spiked to serum, two samples (sample A: 84.4 and sample B: 326 ng/ml) were spiked with 3 different amounts of apoB-48 (21.6, 47.5, and 67.9 ng/ml to sample A, and 243, 495, and 730 ng/ml to sample B), and assayed. Spiked apoB-48 was fully recovered by this ELISA system. Recovery rates of the apoB-48 in sera were 95.4-104%, and 93.4-105%, respectively. Dilution linearity: When 2 different sera were diluted to 2×, 4×, and 8× by assay buffer, and assayed together with original undiluted sera, excellent linear lines were obtained with very high R 2 (Fig. 7) . This shows that the assay system is not influenced by other serum components, and gives the same assay value at any dilution.
Concentrations of apoB-48 in serum samples from normal rabbits
Healthy NZW male rabbits of 10 weeks of age fed on a standard diet for rabbits (LRC-4, Oriental Yeast Co., Ltd.) showed low blood apoB-48 and triglyceride levels. Seven days after switching to the high fat diet, the rabbits showed increased blood apoB-48 and triglyceride levels. Even after 18 h fasting, the levels were about 4 times higher than those on Day 1, and soon after re-starting the high fat diet the levels of both markers showed further increases, reaching their maximum levels 3 h later, before decreasing (Fig. 8) . ANOVA analyses of these changes showed very high significance (P<0.0001). Triglyceride and apoB-48 levels changed in parallel, and the correlation of these markers is shown in Fig. 9 .
Effect of ezetimibe administration on blood levels of apoB-48, triglyceride, and cholesterol
Ezetimibe was developed by the Schering-Plough Fig. 6 . Correlation between standard curves. Comparison between the standard curve using the rabbit preparation obtained by immuno-affinity chromatography and that using the recombinant human apoB-48. Standard curves were prepared of absorbance against protein weight, and their absorbances were compared.
Fig. 7.
Dilution linearity of apoB-48 in serum. Two sera with different concentrations of apoB-48 were prepared. The sera were diluted serially by dilution buffer (50 mM Tris-HCl buffer, pH 7.5, 0.15 M NaCl, 0.1% TritonX-100), and assayed.
Research Institute and is known to be a drug that inhibits cholesterol transporter, NPC1L1, in the upper small intestine and cholesterol absorption [1] . Starting on Day 1, NZW rabbits were fed on the high fat diet throughout the experimental period, and from Day 8, half of the rabbits were orally given ezetimibe, 0.6 mg/kg body weight/day suspended in 3 ml of physiological saline, for 2 weeks, while other rabbits, serving as controls, were given 3 ml of physiological saline. After switching to the high fat diet, blood levels of apoB-48, triglyceride, and cholesterol showed marked increases. These levels continued increasing in control animals until the last day of the experiment with large variation. Significant differences of variance were observed between the control and ezetimibe groups in triglyceride and cholesterol levels (P<0.01) on Days 15 and 22. The variation of the apoB-48 levels in the control group also increased, however, no significant differences from the ezetimibe group were observed. No further increases of these three markers were observed in the group given ezetimibe, and the variations of these markers remained small (Fig. 10) .
Discussion
We prepared an anti-apoB-48 monoclonal antibody, 4C8, using a synthetic peptide against C-terminal decapeptide of human apoB-48, and with this antibody we established an ELISA system for human apoB-48 with an excellent specificity [8] . In this report, we further examined if this assay system could be applied to rabbit apoB-48, because of the high homology of the C-terminal decapeptide sequence between human and rabbit apoB-48. The cross-reactivity of the monoclonal antibody was confirmed by dot blot test using the C-terminal decapeptide of rabbit apoB-48 (Fig. 1) , SDS-PAGE, and the western blot test using rabbit serum samples (Fig.  2) . We could also isolate rabbit apoB-48 by affinity chromatography using anti apoB-48 monoclonal antibody (4C8) (Figs. 3 and 4) . In the present assay system we used this preparation as the standard of rabbit apoB-48.
We could not use recombinant preparation of rabbit apoB-48, because the complete amino acid sequence of rabbit apoB-48 has not been elucidated. So, we compared two standard curves, one with the substance obtained by immuno-affinity chromatography using the antibody against C-terminal decapeptide, and theother lyceride in male rabbits. Four healthy NZW male rabbits of 10 weeks of age, body weight 2.5-3.0 kg, were fed on a high fat diet for 7 days, and after fasting for 18 h, the same high fat diet was given for a further 1 h. Blood samples were collected at 1, 3, 6, and 9 h from the ear vein after re-feeding. Mean of 2 rabbits and SE. with human recombinant apoB-48 [17] . They showed an excellent correlation with R 2 =0.9996 and the slope of the first order regression equation was 1.0122. This evidence is supportive of our claim that this ELISA system can measure rabbit apoB-48. It has been reported that treatment of serum with TritonX-100 increases the recognition of apoB-48 epitope by hexapeptide antibodies [2, 4, 16] . In our previous study, we found that our monoclonal antibody (4C8) showed different characteristics in the recognition site of apoB-48 from the other hexapeptide polyclonal or monoclonal antibodies hitherto reported [10, 12, 16] .
An excellent standard curve was obtained (Fig. 5) , and we validated the ELISA system to show its usefulness. The assay precision and reproducibility are considerably good with small variances. The spike recovery test was permissible, and the dilution linearity test indicated that this system is not influenced by blood components (Fig.  7) .
The suitability of the ELISA method was established at fasting and during the postprandial follow-up of a group of healthy rabbits. Blood levels of apoB-48 in rabbits fed on standard diet were rather low, about 1 µg/ ml. The level increased by switching to the high fat diet, and even after 18 h of fasting the level was about 4-fold that of the normal state. After restart of feeding, the level showed further increase and reached a maximum level 3 h later (Fig. 8) . In this experiment, a significant correlation was observed between apoB-48 and triglyceride levels (Fig. 9) , indicating that the changes of apoB-48 concentration corresponded to the expected transient accumulation of CM particles in circulation after ingestion of the high fat diet [11] .
We also observed the effect of ezetimibe on blood apoB-48 levels during the high fat diet Ezetimibe is known to be a drug that inhibits cholesterol transporter, NPC1L1, in the upper intestine and cholesterol absorption [1] . The standard diet was switched to the high fat diet on the first day. At this point, blood apoB-48, triglyceride and cholesterol levels were low. Ezetimibe, given orally (daily dose: 0.6 mg/kg) from Day 8 on, successfully inhibited further increase of apoB-48, triglyceride and cholesterol compared with controls (Fig.  10) .
These observations are in line with the notion that , and cholesterol (C) before and after ezetimibe administration. Both groups were given the high fat diet starting on Day 1 throughout the experimental period. Rabbits in group 1 were orally administered etizemibe, 0.6 mg/kg body weight/day suspended in 3 ml of physiological saline for 2 weeks starting on Day 8, while rabbits in group 2 served as the control and were given 3 ml of physiological saline. Blood samples were collected on Days 1, 8, 15, and 22 from the ear vein. : Control, : ezetimibe administration, Mean of 3 rabbits and SE. Significance of difference between control and ezetimibe groups: *P<0.05, **P<0.01. Significant differences of variance were observed between control and ezetimibe groups in triglyceride and cholesterol levels on Days 15 and 22.
apoB-48 is a reliable marker of CM and CM remnants.
In conclusion, this new ELISA system using the monoclonal antibody to C-terminal decapeptide of human apoB-48, 4C8, was successfully applied to measurement of rabbit apoB-48. This system is simple, reliable and suitable for routine animal experiments.
